For a 39‑year‑old male with a normal comprehensive metabolic panel, is oral terbinafine appropriate for onychomycosis and what liver function monitoring is required?

Oral Terbinafine for Onychomycosis in a 39-Year-Old Male with Normal CMP

Oral terbinafine 250 mg daily is appropriate first-line therapy for this patient, and baseline liver function tests should be obtained before starting treatment, with periodic monitoring during therapy. 1, 2

Treatment Appropriateness

• Terbinafine is the first-line systemic agent for dermatophyte onychomycosis based on superior efficacy compared to alternatives, achieving complete cure rates of 55% versus 26% for itraconazole at 72 weeks. 1
• The British Association of Dermatologists provides a Grade A recommendation (highest level) for terbinafine as first-choice therapy unless contraindications exist. 1
• With a normal comprehensive metabolic panel, this patient has no contraindication to terbinafine therapy, as the drug is not recommended only in patients with active or chronic liver disease. 1

Dosing Regimen

• Prescribe terbinafine 250 mg orally once daily for 12 weeks for toenail onychomycosis or 6 weeks for fingernail onychomycosis. 1, 2
• For extensive toenail disease, extending treatment to 16 weeks may improve cure rates. 3
• Food intake does not affect absorption, so the medication can be taken with or without meals. 3

Required Liver Function Monitoring

Baseline Testing (Before Starting Treatment)

• Obtain baseline liver function tests (AST and ALT) and complete blood count before prescribing terbinafine. 1, 2
• The FDA label explicitly states: "Measurement of serum transaminases (ALT and AST) is advised for all patients before taking terbinafine tablets." 2
• This baseline testing is mandatory even in patients without liver disease history, as hepatotoxicity can occur in individuals with normal baseline hepatic function. 2

Ongoing Monitoring During Treatment

• Periodic monitoring of liver function tests is recommended during therapy. 2
• In a 2023 retrospective study of 735 patients on terbinafine, 5.2% exhibited elevated AST and 8.4% elevated ALT after one month of treatment, though none required discontinuation for hepatotoxicity. 4
• Intensify monitoring in patients with heavy alcohol consumption, hepatitis history, or concurrent hepatotoxic drug use, even though this patient's normal CMP suggests none of these apply. 1

When to Discontinue

• Immediately discontinue terbinafine if biochemical or clinical evidence of liver injury develops. 2
• Instruct the patient to report symptoms of hepatotoxicity immediately: persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools. 2

Critical Patient Counseling Points

Potentially Permanent Adverse Effects

• Warn the patient about potentially permanent taste disturbance (dysgeusia), which can be severe enough to cause decreased food intake, weight loss, and depressive symptoms. 1, 2
• Taste disturbance may resolve within several weeks after discontinuation but can persist for more than one year or become permanent. 2
• Smell disturbance, including loss of smell, may also occur and can be prolonged or permanent. 2
• If taste or smell disturbance occurs, terbinafine should be discontinued. 2

Other Important Warnings

• Alert the patient to report depressive symptoms, as these have been reported during postmarketing surveillance. 2
• Rare but serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) require immediate discontinuation if progressive skin rash develops. 2
• The incidence of serious adverse events is only 0.04%, with most side effects being mild gastrointestinal (49%) or dermatological (23%) events. 1

Follow-Up Evaluation

• Re-evaluate the patient 3–6 months after treatment initiation to assess response and detect adverse effects. 1, 3
• The optimal clinical effect is seen months after mycological cure and treatment cessation due to the time required for healthy nail outgrowth. 2
• Terbinafine persists in the nail for 6 months after completion of treatment due to its long half-life and lipophilic distribution. 1

Drug Interaction Considerations

• Terbinafine has minimal drug-drug interactions, with the only clinically significant interaction involving drugs metabolized by cytochrome P450 2D6. 1
• This favorable interaction profile distinguishes terbinafine from azole antifungals, which have extensive cytochrome P450-mediated interactions. 5

Common Pitfalls to Avoid

• Do not skip baseline liver function testing even in young, healthy patients with normal CMP, as the FDA label mandates this for all patients. 2
• Do not reassure patients that taste disturbance is always reversible—emphasize the potential for permanence to ensure informed consent. 2
• Do not prescribe terbinafine if the patient has active or chronic liver disease, even if current transaminases are normal. 1, 2
• Ensure mycological confirmation of onychomycosis before treatment when possible, as clinical diagnosis alone has limited accuracy. 2